Glimepiride 4 mg Tablets Under Fasting Conditions

This study has been completed.

Sponsor:

Information provided by:

Teva Pharmaceuticals USA

ClinicalTrials.gov Identifier:

NCT00834340

First received: January 30, 2009

Last updated: September 1, 2009

Last verified: September 2009

History of Changes

Results First Received: June 22, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Bio-equivalence Study; Intervention Model: Crossover Assignment; Masking: Open Label
Condition:	Healthy
Interventions:	Drug: Glimepiride 4 mg Tablets Drug: AMARYL® 4 mg Tablets

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Glimepiride (Test) First	Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
Amaryl® (Reference) First	Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period

Participant Flow for 3 periods

Period 1: First Intervention

	Glimepiride (Test) First	Amaryl® (Reference) First
STARTED	16	16
COMPLETED	16	16
NOT COMPLETED	0	0

Period 2: Washout

	Glimepiride (Test) First	Amaryl® (Reference) First
STARTED	16	16
COMPLETED	14	16
NOT COMPLETED	2	0
Adverse Event	1	0
Withdrawal by Subject	1	0

Period 3: Second Intervention

	Glimepiride (Test) First	Amaryl® (Reference) First
STARTED	14	16
COMPLETED	14	16
NOT COMPLETED	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Glimepiride (Test) First	Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
Amaryl® (Reference) First	Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
Total	Total of all reporting groups

Baseline Measures

	Glimepiride (Test) First	Amaryl® (Reference) First	Total
Number of Participants [units: participants]	16	16	32
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	16	16	32
>=65 years	0	0	0
Gender [units: participants]
Female	4	5	9
Male	12	11	23
Race/Ethnicity, Customized [units: Participants]
Caucasian	3	0	3
Black	4	8	12
Hispanic	8	8	16
Biracial	1	0	1
Region of Enrollment [units: participants]
United States	16	16	32

Outcome Measures

Hide All Outcome Measures

1. Primary:

Cmax - Maximum Observed Concentration [ Time Frame: Blood samples collected over 24 hour period ]

Measure Type	Primary
Measure Title	Cmax - Maximum Observed Concentration
Measure Description	Bioequivalence based on Cmax
Time Frame	Blood samples collected over 24 hour period
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Data from all subjects who completed the study were included in the statistical analysis.

Reporting Groups

	Description
Glimepiride	Glimepiride 4 mg Tablet (test) dosed in either period
Amaryl®	Amaryl® 4 mg Tablet (reference) dosed in either period

Measured Values

	Glimepiride	Amaryl®
Number of Participants Analyzed [units: participants]	30	30
Cmax - Maximum Observed Concentration [units: ng/mL] Mean ± Standard Deviation	231.700 ± 97.290	226.890 ± 88.016

Statistical Analysis 1 for Cmax - Maximum Observed Concentration

Groups ^[1]	All groups
Non-Inferiority/Equivalence Test ^[2]	Yes
Geometric Test/Ref Ratio x 100 ^[3]	101
90% Confidence Interval	( 92.2 to 111 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.
[3]	Other relevant estimation information:
	Bioequivalence is established when 90% Confidence Interval falls within 80-125.

2. Primary:

AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) [ Time Frame: Blood samples collected over 24 hour period ]

Measure Type	Primary
Measure Title	AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Measure Description	Bioequivalence based on AUCinf
Time Frame	Blood samples collected over 24 hour period
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The parameter of AUCinf could not be estimated for one subject.

Reporting Groups

	Description
Glimepiride	Glimepiride 4 mg Tablet (test) dosed in either period
Amaryl®	Amaryl® 4 mg Tablet (reference) dosed in either period

Measured Values

	Glimepiride	Amaryl®
Number of Participants Analyzed [units: participants]	29	29
AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) [units: ng*h/mL] Mean ± Standard Deviation	1613.846 ± 553.310	1660.082 ± 637.392

Statistical Analysis 1 for AUCinf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Groups ^[1]	All groups
Non-Inferiority/Equivalence Test ^[2]	Yes
Geometric Test/Ref Ratio x 100 ^[3]	98.5
90% Confidence Interval	( 94.0 to 103 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.
[3]	Other relevant estimation information:
	Bioequivalence is established when 90% Confidence Interval falls within 80-125.

3. Primary:

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration [ Time Frame: Blood samples collected over 24 hour period ]

Measure Type	Primary
Measure Title	AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration
Measure Description	Bioequivalence based on AUC0-t
Time Frame	Blood samples collected over 24 hour period
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Data from all subjects who completed the study were included in the statistical analysis.

Reporting Groups

	Description
Glimepiride	Glimepiride 4 mg Tablet (test) dosed in either period
Amaryl®	Amaryl® 4 mg Tablet (reference) dosed in either period

Measured Values

	Glimepiride	Amaryl®
Number of Participants Analyzed [units: participants]	30	30
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration [units: ng*h/mL] Mean ± Standard Deviation	1479.961 ± 524.507	1469.352 ± 548.723

Statistical Analysis 1 for AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

Groups ^[1]	All groups
Non-Inferiority/Equivalence Test ^[2]	Yes
Geometric Test/Ref Ratio x 100 ^[3]	102
90% Confidence Interval	( 98.7 to 105 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-t, AUCinf and Cmax.
[3]	Other relevant estimation information:
	Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Principal Investigator is not permitted to discuss or publish trial results.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Manager, Biopharmaceutics
Organization: Teva Pharmaceuticals USA
phone: 1-866-384-5525
e-mail: clinicaltrialqueries@tevausa.com

No publications provided

ClinicalTrials.gov Identifier:	NCT00834340 History of Changes
Other Study ID Numbers:	B036501
Study First Received:	January 30, 2009
Results First Received:	June 22, 2009
Last Updated:	September 1, 2009
Health Authority:	United States: Institutional Review Board

To Top